The Global Action Fund for Fungal Infections (GAFFI) has made the case for paracoccidioidomycosis (PCM) to be listed as a Neglected Tropical Disease (NTD) in a short paper published in Public Library of Science (PLoS) Neglected Tropical Diseases. PCM is endemic to the tropical regions of Latin America. PCM is an important cause of mortality… Read more »
Over 1.1 million cases of fungal keratitis are documented annually, leading to >100,000 perforated or surgically removed eyes and >500,000 blind eyes, according to a team from the University of Manchester, London School of Hygiene and Tropical Medicine and GAFFI. Lottie Brown presented this systematic review at Europe’s premier infection meeting ECCMID (Amsterdam) earlier this… Read more »
From its inception in 2013, GAFFI has focussed on improving the survival chances and impact of chronic illness across the world. GAFFI appointed Professor Patrick Francioli to its Board as part of an internal re-organisation that saw Professor David Denning step down from Board Chairman to Chief Executive of GAFFI and Professor Nigel Lightfoot… Read more »
At the 2nd meeting on Histoplasmosis in the Americas and Caribbean in Manaus, Brazil, March 22-25th 2019, the 80 by 2020 target has been superceded by 100 by 2025 target. By 2025, every country should have access to rapid testing for histoplasmosis (antigen or PCR/molecular) and availability of itraconazole and both standard and lipid formulation… Read more »
Around 1 in 15 people affected by tuberculosis are likely get the treatable fungal infection aspergillosis, according to research published today in the European Respiratory Journal by experts at the University of Manchester (UK) and Gulu Regional Referral Hospital (Uganda). The new knowledge could influence TB programs by helping doctors to identify – and treat… Read more »
As in other low and middle income countries serious fungal infections (SFI) remain neglected in Ghana despite the rising trend globally. Most of these infections are undiagnosed or misdiagnosedleading to no treatment or wrong treatment. Low indices of suspicion among clinicians and gaps in the availability of diagnostics services and antifungal drugs are the identified… Read more »
Antifungal triazole drugs are the mainstay of treatment for fungal diseases in humans and animals, yet their effectiveness is undermined by resistance. Very similar compounds are used on many crops to reduce plant fungal disease and increase yield. Today in Amsterdam, the Global Action Fund for Fungal infections published its letter to the World Health Organisation’s Director… Read more »
For 213 million people, the number affected by serious fungal diseases infections in Ghana, South Africa, Ethiopia and Taiwan has been unknown, until today. At the Gulf Conference on Clinical Microbiology and Infectious Diseases in Dubai posters showed the remarkably high numbers afflicted, especially in Africa, an estimated 4%, 7% 9% and 2% respectively…. Read more »
The Director-General of the World Health Organization (Dr Tedros Adhanom Ghebreyesus) has called for more research into mycetoma, a chronic fungal infection causing severe disfigurement of the hands or feet. Primarily affecting poor outdoor workers (labourers and herdsmen), mycetoma is thought to affect up to 50,000 people worldwide but accurate statistics are not available,… Read more »
Gilead Sciences, a pharmaceutical company with an interest in AIDS, hepatitis C and infectious diseases, have expanded their access initiative for AmBisome (a liposomal preparation of amphotericin B) to include cryptococcal meningitis, where previously it was only for leishmaniasis. Governments and public sector procurers in 116 low- and middle-income countries can now buy the drug… Read more »
